89 completed, 30 recruiting, 19 unknown, 16 terminated. 72 Not applicable, 35 Phase 2, 14 Phase 3, 11 Phase 1, 2 Phase 4.
Follow Institut Curie: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Modelization of Early Endometrial-trophoblast Molecular Interaction Diagnostic hysteroscopy with endometrial biopsy - Infertility, Eclampsia Preeclampsia | Not applicable | Not yet recruiting | Centre Hospitalier Intercommunal Creteil | 500 | 2026-10-01 | 2026-09-17 |
| Omission of Surgery for Triple-negative Breast Cancer in Complete Response After Neoadjuvant Chemo-immunotherapy Omission of surgery - Triple Negative Breast Cancer, Non-Metastatic | Not applicable | Not yet recruiting | Institut Curie | 150 | 2026-08-01 | 2026-06-03 |
| Validation of Capillary Microsampling for Therapeutic Drug Monitoring of CDK4/6 Inhibitors in Breast Cancer Patients (TDHOME) Capillary samples using the VAMS Mitra device - Breast Cancer | Not applicable | Recruiting | Institut Curie | 90 | 2026-06-23 | 2026-07-23 |
| Adherence to Enteral Nutrition Enteral Nutrition | Recruiting | Institut Curie | 80 | 2026-03-05 | 2026-05-06 | |
| Comparison of 18F Labeled Analog of MIBG (18F-MFBG) PET/CT and 123I-MIBG SPECT in Pediatric Patients With Neuroblastoma. 18F-MFBG PET/CT imaging - Neuroblastoma | Phase 2 | Not yet recruiting | Institut Curie | 30 | 2026-03-01 | 2025-09-03 |
| Tucatinib and Trastuzumab in HER3-mutant and HER2-not Amplified Metastatic Breast Cancer Tucatinib (ONT-380), Trastuzumab (Herceptin) - Metastatic Breast Cancer ( HER2 Negative), Unresectable Breast Cancer | Phase 2 | Recruiting | Institut Curie | 20 | 2026-01-31 | 2026-02-23 |
| Early Detection of Triple Negative Breast Cancer Relapse (CUPCAKE) ctDNA monitoring, 68Ga-FAPI-46-PET-CT - Triple Negative Breast Cancer | Not applicable | Recruiting | Institut Curie | 450 | 2026-01-05 | 2026-07-23 |
| Cutting Edge Imaging With PET-FAPI for Earlier Pancreatic Cancer Diagnosis (INDIGO-FAPI) 68Ga-FAPI-46 for PET / CT scan - Pancreatic Ductal Adenocarcinoma (PDAC) | Phase 2 | Recruiting | Institut Curie | 35 | 2025-12-02 | 2026-04-15 |
| Mechanics of Human Pre Implantation Development Infertility | Not yet recruiting | Assistance Publique - Hôpitaux de Paris | 1500 | 2025-11-01 | 2025-09-12 | |
| Screening and Care for Fear of Cancer Recurrence in Patients With Cancer at Institut Curie Lung Cancer, Breast Cancer | Recruiting | Institut Curie | 200 | 2025-09-08 | 2026-01-23 | |
| Defining Dosimetric Reference Levels in Computed Tomography Spectral Scanning Spectral ComputedTomography - Medical Imaging | Active not recruiting | Centre Hospitalier Universitaire de Nīmes | 9600 | 2025-09-01 | 2026-10-21 | |
| Skin Reactions Related to Thoracic Implantable Chamber Dressings Skin Diseases | Recruiting | Institut Curie | 500 | 2025-06-10 | 2025-09-08 | |
| Comparative Evaluation of Care Strategies on Dressing Change-induced Bleeding in Patients With Bleeding Malignant Wounds (Tumoss) Algosteril, Other Dressings: interface, hydrocellular, hydrofiber - Malignant Wound | Not applicable | Terminated | Institut Curie | 4 | 2025-03-27 | 2026-04-22 |
| Optimizing Bronchopulmonary Cancer Screening Screening, Inclusion, Chest CTscan and follow-up - Bronchopulmonary Disease, Diagnoses Disease | Not applicable | Recruiting | Institut Curie | 500 | 2025-01-27 | 2026-09-10 |
| A Study on Tuvusertib (Oral ATR Inhibitor) in Combination With PLX038 (Topo1 Inhibitor) in Patients With Advanced Solid Tumors PLX038 + Tuvusertib - Solid Tumor | Phase 1 | Terminated | Institut Curie | 10 | 2025-01-20 | 2026-01-02 |
| Efficacy of Personalized Tumorogram-based Therapy in Cancer Established From Patient-derived Organoid (AVATAR) Biopsy - Metastatic Breast Cancer | Not applicable | Recruiting | Institut Curie | 110 | 2024-12-06 | 2026-01-29 |
| Retrospective Analysis of the Efficacy of Morphine Gel to Treat Pain Associated With Perineal RadioDermatitis morphine chlorhydrate in intrasite gel - Dermatitis, Radiation Induced | Completed | Institut Curie | 17 | 2024-12-01 | 2025-10-06 | |
| 68Ga-FAPI-46 PET/CT for Predicting Histological Response in Triple-negative Breast Cancer (FAP-IT) 68Ga-FAPI-46 PET/CT imaging - Triple Negative Breast Cancer | Not applicable | Recruiting | Institut Curie | 60 | 2024-10-14 | 2025-12-22 |
| Validation of the European Oncology Quality of Life Toolkit Administration of the EUonQoL-Kit - Active Treatment questionnaire, Administration of the EUonQoL-Kit - Survivors questionnaire, Administration of the EUonQoL-Kit - Palliative Care questionnaire - Cancer, Survivorship | Unknown | Fondazione IRCCS Istituto Nazionale dei Tumori, Milano | 4000 | 2024-08-31 | 2024-08-20 | |
| Efficacy Assessment of Lenvatinib Associated with Pembrolizumab in Metastatic Endometrial Cancer: a French Multicentric Retrospective Early Access Program-based Study Metastatic Endometrial Cancer | Completed | ARCAGY/ GINECO GROUP | 351 | 2024-08-19 | 2025-03-20 |
Showing 20 of 172. Sign in to see all of them.
Breast Neoplasms (38) · Neoplasms (31) · Uveal Melanoma (13) · Neoplasm Metastasis (10) · Triple Negative Breast Neoplasms (9) · Neuroblastoma (6) · Ovarian Neoplasms (5) · Retinoblastoma (5) · Uterine Cervical Neoplasms (5) · Brain Neoplasms (4) · Lung Neoplasms (4) · Lymphoma (3) · Melanoma (3) · Neoplastic Cells, Circulating (3) · Neuroectodermal Tumors, Primitive, Peripheral (3)
Blood Specimen Collection (21) · Biopsy (6) · Surveys and Questionnaires (5) · Trastuzumab (5) · Drug Therapy (4) · Radiotherapy (4) · Bevacizumab (3) · Carboplatin (3) · Etoposide (3) · Ropivacaine (3) · Vincristine (3) · Ado-Trastuzumab Emtansine (2) · Cisplatin (2) · Cyclophosphamide (2) · Fitness Trackers (2)
France (166) · Germany (6) · Netherlands (6) · United Kingdom (6) · Italy (5) · Spain (5) · Switzerland (5) · Belgium (4) · Austria (3) · Denmark (3) · Israel (3) · Serbia (3) · Czechia (2) · Norway (2) · Portugal (2)
Manuel Rodrigues, MD (2) · Maya Gutierrez, MD (2) · Pascale Mariani, MD (2) · Sophie Piperno-Neumann, MD (2) · Alex De Caluwe, MD (1) · Aline H Albi-Feldzer, MD (1) · Andrieu Nadine, PhD (1) · Anne-Isabelle Bertozzi-Salamon, MD (1)
PMID 23340351, PMID 11020770, PMID 16698416, PMID 19903919, PMID 22706476, PMID 23340346, PMID 23934701, PMID 25274615, PMID 25355723, PMID 25700777, PMID 25724520, PMID 26328937, PMID 26342236, PMID 26531748, PMID 27993804, PMID 29339446, PMID 29635147, PMID 29776920, PMID 30212804, PMID 30282798, PMID 30392813, PMID 30698644, PMID 30785830, PMID 32002287, PMID 32712650, PMID 32739563, PMID 32750212, PMID 32928264, PMID 32971187, PMID 33151266, PMID 33676547, PMID 33722295, PMID 33865379, PMID 34355741, PMID 34362344, PMID 34455229, PMID 34615705, PMID 35019850, PMID 35294527, PMID 35399119, PMID 35418195, PMID 35508697, PMID 35525718, PMID 35834762, PMID 35863105, PMID 36301572, PMID 36847256, PMID 36974007, PMID 36999900, PMID 37296901
2009 (2), 2023 (2), 2008 (1), 2014 (1), 2016 (1), 2019 (1)